PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6613796

Hyperlipidemia.

R W Sloan
View original source ↗Export metadata ↓

Abstract

Ten percent of the U.S. population has hyperlipidemia. The most commonly encountered phenotypes include Type IIa, Type IIb and Type IV. Anion-exchange resins are the drugs of choice for hypercholesterolemia, while gemfibrozil is the preferred agent for massive hypertriglyceridemia. Clofibrate is the drug of choice for the rare Type III hyperlipidemia. Successful management begins with evaluation of the total clinical picture, including genetic factors, measurement of cholesterol and triglycerides, and visual examination of the serum.

Explore related subjects

ChylomicronsHumansHyperlipidemiasLipoproteins, HDLLipoproteins, LDLLipoproteins, VLDLRiskTriglyceridesJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R W Sloan. 1983. Hyperlipidemia.. https://pubmed.ncbi.nlm.nih.gov/6613796/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

Diets and postprandial lipoproteins.

The postprandial phase is characterized by a temporary accumulation of atherogenic chylomicron remnants and activation of coagulation factor VII. The benefits of diets recommended to decrease the risk of coronary heart disease should also be evaluated in this respect. Although most of the recent dietary studies included a postprandial evaluation, a large majority were conducted using conventional methods. Consequently they have only provided a limited insight into the changes of the above mentioned risk factors. Furthermore, it should be realized that evaluations made under conditions in which an individual is prepared for a cholesterol-lowering diet do not provide an accurate risk estimation. Thus, evaluations should be performed preferably in the free-living situation.

Chylomicrons↗
PubMed1994

Lipoprotein lipase: structure, function and mechanism of action.

Lipoprotein lipase (LPL) plays a central role in the hydrolysis of circulating triglycerides present in chylomicrons, and very low density lipoproteins. The active form of the enzyme is a non-covalent homodimer which contains multiple functional domains required for normal hydrolytic activity including a catalytic domain, as well as sites involved in co-factor, heparin and lipid binding. Recent studies involving site-directed mutagenesis, the elucidation of the three dimensional crystallographic structure of different lipases, as well as analysis of the molecular defects that result in the expression of the familial chylomicronemia syndrome have provided new insights into the structure-function relationship of LPL. As a result, our understanding of structural domains involved in catalysis, heparin, lipid binding, and enzyme-cofactor interaction as well as the mechanism of action of LPL as an acylglycerol hydrolase has been greatly enhanced.

Chylomicrons↗